March 4th, 2013

Innovations in Biologics Discovery and Development


SABPA Science & Technology Forum – Innovations in Biologics Discovery and Development (March 23, 2013)


Innovations in Biologics Discovery and Development


Date:                March 23, 2013, Saturday, 8:30am to 1:00pm (Breakfast and lunch will be provided)

Location:         Institute of Americas, UCSD, (Direction available at


$20 for online registration, $10 for students and  post-docs. $40 for on-site registration, Online registration ends March 20, 2012


For the past two decades, biologics have revolutionized the treatment of diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease, diabetes, multiple sclerosis, and are widely used in treating a variety of cancers. Biologics is a rapidly developing field of therapeutics and there is a trend for pharmaceutical and biotech industries to drift toward biologics development due to the promise of biologic drugs.


At the SABPA Science & Technology Forum XI, we bring together leaders in academia and the pharma/biotech industry to discuss current trends in biologics discovery and development, as well as challenges in the field. The presentations will address new technologies in discovering novel biologic therapeutics including the use of unnatural amino acids, somatic hypermutation and directed molecular evolution as well as developing biologics delivery platforms. The meeting will cover therapeutic antibodies, proteins, peptides, vaccines and therapeutic areas from cancers, autoimmune to cardiovascular diseases.

Event Program


8:00-8:30 Registration & Breakfast
8:30-8:35 Opening Remarks
8:35-8:40 Chairperson of session 1
8:40-9:15 Peter Schultz, Ph.D.

Professor of Chemistry, Scripps Research Institute; and Director of California Institute for Biomedical Research

Title:A Chemist’s Foray into Translational Medicine.

9:15-9:45 Thomas F Bumol, Ph.D.

Vice President of Biotechnology and Autoimmunity, Lilly Research Laboratories, Lilly Biotechnology Center-San Diego

Title: Biotechnology as a Sustainable Source of Pharmaceutical Innovation: the Lilly Biotechnology Strategy.

9:45-10:15 David King, Ph.D.

Chief Scientific Officer, AnaptysBio Inc

Title: Generating Improved Antibody Therapeutics through Somatic Hypermutation in vitro

10:15-10:40 Refreshment Break, Exhibit & Networking
10:40-10:45 Chairperson of session 2
10:45-11:15 Jeremy Barton, M.D.

Vice President, Biotherapeutics Development, Pfizer

Title: Antibody Drug Conjugates: Blockbusters of the Next Decade?

11:15-11:45 Henry Ji, Ph.D.

Chief Executive Officer and President, Sorrento Therapeutics

Title: The G-MAB®Library Technology-Discovery and Development of New Human Therapeutic Antibodies

11:45-12:45 Panel Discussion: Biologics Development


Steve Prestrelski, Ph.D., M.B.A.

Chief Scientific Officer, Xeris Pharmaceuticals, Inc.


1. Bhawanjit Brar, Ph.D., Senior Director, Zensun USA

2. Jean I Liu, M.S., J.D., Vice President, General Counsel and Secretary, Halozyme Therapeutics, Inc.

3. Brenden S. Gingrich, Ph.D., J.D., Partner, Knobbe Martens

4. Tim Tian, Ph.D., Senior Scientist, Laureate BioPharma

5. Olivier Laurent, Ph.D., Director, Protein Science, CovX

12:45-12:50 Closing Remarks
12:50-14:30 Lunch